百克生物表示，2025年度业绩变动主要受民众对疾病认知程度、疫苗消费意愿等多方面因素影响，部分 已确认收入的带状疱疹减毒活疫苗到效期而未能实现接种发生退货，导致收入下降；为增强公众对带状 疱疹的预防意识，履行企业社会责任，提升疫苗接种普及率，公司积极推进惠民项目、主动进行价格调 整，带状疱疹疫苗单价下降，导致收入下降；此外，因新生儿出生率下降及市场竞争加剧，公司水痘减 毒活疫苗销量同比减少，导致收入下降。 北京商报讯（记者 丁宁）2月26日晚间，百克生物（688276）发布2025年业绩快报显示，公司2025年度 实现营业收入5.92亿元，同比下降51.85%；归属净利润-2.72亿元，上年同期2.32亿元，同比由盈转亏。 ...

2025年度业绩变动主要受民众对疾病认知程度、疫苗消费意愿等多方面因素影响，部分已确认收入的带 状疱疹减毒活疫苗到效期而未能实现接种发生退货，导致收入下降；为增强公众对带状疱疹的预防意 识，履行企业社会责任，提升疫苗接种普及率，公司积极推进惠民项目、主动进行价格调整，带状疱疹 疫苗单价下降，导致收入下降；此外，因新生儿出生率下降及市场竞争加剧，公司水痘减毒活疫苗销量 同比减少，导致收入下降。 智通财经APP讯，百克生物(688276.SH)发布2025年度业绩快报，报告期内，公司营业总收入5.92亿元， 同比下降51.85%;归属于母公司所有者的净利润-2.72亿元，上年同期23,209.38万元，同比下降 217.22%。 ...

格隆汇2月26日丨百克生物(688276.SH)公布2025年度业绩快报，报告期内，公司营业总收入5.92亿元， 同比下降51.85%；归属于母公司所有者的净利润-2.72亿元，同比下降217.22%；归属于母公司所有者的 扣除非经常性损益的净利润-2.89亿元，同比下降225.71%。 2025年度业绩变动主要受民众对疾病认知程度、疫苗消费意愿等多方面因素影响，部分已确认收入的带 状疱疹减毒活疫苗到效期而未能实现接种发生退货，导致收入下降；为增强公众对带状疱疹的预防意 识，履行企业社会责任，提升疫苗接种普及率，公司积极推进惠民项目、主动进行价格调整，带状疱疹 疫苗单价下降，导致收入下降；此外，因新生儿出生率下降及市场竞争加剧，公司水痘减毒活疫苗销量 同比减少，导致收入下降。 ...

Core Viewpoint - The company reported a significant decline in both revenue and net profit for the fiscal year 2025, primarily influenced by various factors affecting public awareness and willingness to consume vaccines [1] Financial Performance - Total operating revenue for the year was 592 million yuan, representing a year-on-year decrease of 51.85% [1] - Net profit attributable to the parent company was -272 million yuan, a year-on-year decline of 217.22% [1] - Net profit attributable to the parent company, excluding non-recurring gains and losses, was -289 million yuan, reflecting a year-on-year decrease of 225.71% [1] Factors Influencing Performance - The decline in revenue was attributed to several factors, including public awareness of diseases and willingness to receive vaccinations [1] - The company faced returns on confirmed revenue from the herpes zoster live attenuated vaccine due to expiration before administration, contributing to the revenue drop [1] - To enhance public awareness of herpes zoster prevention and fulfill corporate social responsibility, the company actively promoted welfare projects and adjusted prices, leading to a decrease in the unit price of the herpes zoster vaccine, which further impacted revenue [1] - Additionally, a decline in newborn birth rates and increased market competition resulted in reduced sales of the varicella live attenuated vaccine, further contributing to the revenue decline [1]

Group 1 - Yunnan Baiyao plans to invest 137 million yuan in the second phase of its oral liquid project to meet growing market demand for its products [1] - Hanma Technology's subsidiary intends to increase capital by 575 million yuan in Shanghai Suoda and transfer 100% of its shares for 485 million yuan [2] - JiaoKong Technology won a contract worth 16.8 million euros for a project in Turkey, expected to be operational by December 2028 [3] Group 2 - Hanhui Technology's shareholder plans to reduce their stake by up to 1.86% [4] - Haisheng Pharmaceutical reported a 32.72% increase in revenue and a 36.89% increase in net profit for 2025 [5] - Oukang Pharmaceutical's net profit for 2025 decreased by 48.21% despite a 7.73% increase in revenue [6] Group 3 - Huaihe Energy expects a net profit of 1.684 to 1.784 billion yuan for 2025, a year-on-year increase of 96.31% to 107.97% [7] - Watson Bio received approval for clinical trials of its varicella vaccine [8] - ShunNa Co. plans to reduce its stake by up to 1% [9] Group 4 - Chutianlong intends to raise up to 760 million yuan through a private placement [10] - Yifang Technology's shareholders plan to reduce their holdings by up to 34,830 shares [12] - Yunjigroup's subsidiary signed an EPC contract worth 1.331 billion yuan [13] Group 5 - Jianghuai Automobile reported a 2.14% decrease in January sales [15] - Lifan Pharmaceutical participated in a national procurement program and aims to be selected for three products [16] - Magu Technology's shareholder plans to reduce their stake by up to 3% [17] Group 6 - Jianghuai Automobile's private placement raised approximately 3.5 billion yuan, with investor Ge Weidong subscribing for 1 billion yuan [18] - Huichuan Technology expects a net profit increase of 16% to 26% for 2025 [19] - Hezhong China reported a 10.24% decrease in January consolidated revenue [20] Group 7 - Zhongjian Technology plans to invest 30 million yuan in a new fund focused on new energy [22] - Kanda New Materials intends to invest 646 million yuan in a new production project [23] - Yuegui Co.'s subsidiary obtained a mining license [25] Group 8 - TBG Technology plans to invest 1.53 billion yuan in a new project [27] - Xiexin Integration stated it currently lacks production capacity in the "space photovoltaic" sector [28] - Shibao Testing's controlling shareholder plans to transfer 8.5% of the company's shares [29] Group 9 - TeBao Bio reported a 31.18% increase in revenue and a 25.39% increase in net profit for 2025 [30] - Guoke Tiancai reported a 14.73% increase in revenue and a 17.94% increase in net profit for 2025 [31] - Miaokelando signed a memorandum with SADAFCO to explore the children's cheese snack market in Saudi Arabia [32] Group 10 - Tangrenshen reported a 25.6% decrease in January sales revenue [33] - Northeast Securities received approval to establish a subsidiary in Hong Kong [34] - Yiyi Co. terminated its asset acquisition plan due to changes in the target company's performance [35] Group 11 - Wushang Group's major shareholder plans to reduce their stake by up to 3% [36] - Weigang Technology's shareholder plans to reduce their stake by up to 2.98% [37] - Yutong Technology plans to acquire 51% of Huayan Technology for 449 million yuan [38] Group 12 - Huasan Pharmaceutical's shareholder plans to reduce their stake by up to 3% [39] - Runbei Hangke's major shareholder plans to reduce their stake by up to 3% [41] - Huada Technology plans to acquire 100% of Huayi Microelectronics for 2.996 billion yuan [42] Group 13 - ST Lifang's stock will resume trading after completing self-inspection work [43]

公司研发的本疫苗为采用水痘-带状疱疹病毒（Varicella-zoster virus,VZV）减毒株接种人二倍体细胞， 经冻干工艺制成的减毒活疫苗。接种本疫苗后，可刺激机体产生抗水痘-带状疱疹病毒的免疫力，用于 预防水痘。 格隆汇2月10日丨沃森生物(300142.SZ)公布，由云南沃森生物技术股份有限公司及子公司云南疫苗实验 室有限公司、北京沃森创新生物技术有限公司和玉溪沃森生物技术有限公司联合研发并共同申请临床试 验的水痘减毒活疫苗，于近日获得国家药品监督管理局签发的《药物临床试验批准通知书》。通知书编 号为：2026LP00378。注册分类：预防用生物制品。审批结论：根据《中华人民共和国药品管理法》 《中华人民共和国疫苗管理法》及有关规定，经审查，2025年11月20日受理的水痘减毒活疫苗符合药品 注册的有关要求，同意开展预防水痘的临床试验。药物临床试验应当自批准之日起3年内实施，3年内未 有受试者签署知情同意书的，本件自行失效。 ...

公告显示，该疫苗为采用水痘-带状疱疹病毒减毒株接种人二倍体细胞，经冻干工艺制成的减毒活疫 苗。接种该疫苗后，可刺激机体产生抗水痘-带状疱疹病毒的免疫力，用于预防水痘。目前国内有六家 企业的水痘减毒活疫苗已获批上市许可。 北京商报讯（记者 王寅浩 宋雨盈）2月10日，沃森生物发布公告称，由公司及子公司云南疫苗实验室有 限公司、北京沃森创新生物技术有限公司和玉溪沃森生物技术有限公司联合研发并共同申请临床试验的 水痘减毒活疫苗，于近日获得国家药品监督管理局签发的《药物临床试验批准通知书》，同意开展预防 水痘的临床试验。 ...

格隆汇2月10日｜沃森生物公告，公司及子公司云南疫苗实验室有限公司、北京沃森创新生物技术有限 公司和玉溪沃森生物技术有限公司联合研发并共同申请临床试验的水痘减毒活疫苗，于近日获得国家药 品监督管理局签发的《药物临床试验批准通知书》，同意开展预防水痘的临床试验。 ...

Core Viewpoint - The company expects a significant decline in net profit for 2025, projecting a range between 49 million to 73 million yuan, representing a year-on-year decrease of 63.8% to 75.7% [1] Group 1: Financial Performance - The company reported a slight increase in operating revenue compared to the previous year [1] - The overseas business generated revenue of 98.8353 million yuan, marking a substantial year-on-year increase of 859.4% [1] Group 2: Strategic Initiatives - The company is enhancing market promotion and qualification work for new products, including freeze-dried human rabies vaccine and varicella live attenuated vaccine, to improve market share of core products [1] - The company is steadily advancing its international strategy and expanding its overseas business layout [1]

Core Insights - Vaccine hesitancy is spreading from adults to children, leading to a significant decline in vaccination willingness, which has impacted company performance in the vaccine industry [1][2] Company Performance - Changchun BAK Biotech Co., Ltd. (百克生物) expects a net profit loss of 220 million to 280 million yuan for 2025, marking a year-on-year decline of 194.79% to 220.64%, the first annual loss since its listing in 2021 [1][2] - Chongqing Zhifei Biological Products Co., Ltd. (智飞生物) anticipates a loss exceeding 10 billion yuan for 2025, contrasting sharply with its net profit of over 10 billion yuan in 2021, indicating extreme volatility in performance over five years [1] - In the first three quarters of 2025, 11 sample companies in the vaccine sector reported total revenue of 17.4 billion yuan, a significant year-on-year decrease of 49.2%, and a combined net profit loss of 900 million yuan, down 121.6% [1][6] Market Dynamics - The vaccine industry is facing multiple pressures, including increased vaccine hesitancy, significant price declines, severe supply-demand imbalances, and intensified homogenization of competition [2][5] - The price of BAK Biotech's shingles vaccine was reduced from 1,369 yuan to 464 yuan, a nearly 70% decrease, aimed at improving accessibility and stimulating market demand [4] - The overall demand in the vaccine industry is weak, with core products like HPV and flu vaccines experiencing both declining issuance volumes and prices [5][6] Industry Challenges - The vaccine sector has entered a fierce price war, with many products seeing record price drops; for instance, the price of the two-valent HPV vaccine fell from 329 yuan to 86 yuan, and the three-valent flu vaccine was priced as low as 5.5 yuan [5][6] - The price war is attributed to a combination of factors, including decreased willingness for self-funded vaccinations and a shift in procurement strategies by health authorities [6] - The China Vaccine Industry Association has called for a halt to bidding below cost to encourage rational competition within the industry [6] Strategic Responses - Companies are beginning to differentiate themselves to escape the price war; BAK Biotech is diversifying its R&D pipeline, while Zhifei Biological is investing in new areas like GLP-1 [7] - Companies are urged to abandon price competition in favor of differentiated strategies that focus on unmet clinical needs and increased R&D investment to foster sustainable industry growth [7]